tiprankstipranks
Advertisement
Advertisement
Buy Rating on VIZZ Underscored by Improving Prescription Trends and Long-Term Upside Despite Near-Term Revenue Revisions
PremiumRatingsBuy Rating on VIZZ Underscored by Improving Prescription Trends and Long-Term Upside Despite Near-Term Revenue Revisions
1M ago
Lenz Therapeutics price target lowered to $29 from $35 at BofA
Premium
The Fly
Lenz Therapeutics price target lowered to $29 from $35 at BofA
1M ago
Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)
Premium
The Fly
Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)
1M ago
Short Report: VNET Group short interest at 4-month high
PremiumThe FlyShort Report: VNET Group short interest at 4-month high
3M ago
Lenz Therapeutics price target lowered to $35 from $52 at BofA
Premium
The Fly
Lenz Therapeutics price target lowered to $35 from $52 at BofA
3M ago
LENZ Therapeutics: Early VIZZ Launch, Targeted DTC Campaign, and Differentiated Presbyopia Profile Underpin Buy Rating
Premium
Ratings
LENZ Therapeutics: Early VIZZ Launch, Targeted DTC Campaign, and Differentiated Presbyopia Profile Underpin Buy Rating
4M ago
Overreaction to LENZ Therapeutics’ Stock Decline Presents Buying Opportunity Despite Isolated Retinal Tear Incident
PremiumRatingsOverreaction to LENZ Therapeutics’ Stock Decline Presents Buying Opportunity Despite Isolated Retinal Tear Incident
5M ago
Lenz Therapeutics selloff Friday an overreaction, says H.C. Wainwright
Premium
The Fly
Lenz Therapeutics selloff Friday an overreaction, says H.C. Wainwright
5M ago
LENZ Therapeutics: Buy Rating Affirmed Amid Overreaction to Isolated Adverse Event
Premium
Ratings
LENZ Therapeutics: Buy Rating Affirmed Amid Overreaction to Isolated Adverse Event
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100